2024-10-30 - Analysis Report
## Analysis of Merck & Co Inc (MRK) Stock

### 1. Performance Comparison:

Merck & Co Inc (MRK) has a **cumulative return of 61.17%**, lagging behind the S&P 500 (VOO) with **136.74%**. The **relative divergence is -75.57%**, meaning MRK has underperformed the S&P 500 by 75.57%. This puts it in the **10.26th percentile** of its historical performance range, indicating it has performed relatively poorly compared to its past performance against the S&P 500.

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

### 2. Recent Price Movement:

* **Closing Price:** $103.73 (Last Market: $103.81)
* **5-Day Moving Average:** $104.84
* **20-Day Moving Average:** $108.29
* **60-Day Moving Average:** $113.10

The stock is currently trading below all three moving averages, indicating a possible downward trend.

### 3. Technical Indicators Analysis:

* **RSI:** 22.7 - The RSI is below 30, indicating oversold conditions, potentially suggesting a rebound is due.
* **PPO:** -0.37 - The PPO is negative, also indicating weakness in the price momentum.
* **Delta_Previous_Relative_Divergence:** -20.49 - The recent relative divergence has been declining, suggesting a short-term downward trend.
* **Expected Return:** 0.0% - While currently the stock is underperforming the S&P 500, the expected return over the long term (2+ years) with a consistent investment approach is close to the market average, aligning with S&P 500 performance.

### 4. Recent Earnings and Outlook:

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | $16.11B |
| 2024-05-03 | 1.88 | $15.78B |
| 2023-11-03 | 1.87 | $15.96B |
| 2023-08-07 | -2.35 | $15.04B |
| 2024-08-05 | -2.35 | $15.04B |

The most recent earnings (2024-08-05) were **above analyst expectations**. Merck continues to demonstrate consistent revenue growth, with the most recent quarter seeing a significant increase. However,  it is crucial to note the fluctuations in EPS, reflecting the company's strategic adjustments and market dynamics. 

**Further analysis of the earnings data would require a detailed comparison of actual vs. estimated figures, examining factors like market competition, product performance, and operational costs.**

### 5. Financial Information:

**1) Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |
| 2023-06-30 | $15.04B | 73.24% |

Merck has shown consistent revenue growth and strong profit margins, indicating healthy profitability.

**2) Capital and Profitability:**

| Quarter  | Equity     | ROE |
|---|---|---|
| 2024-06-30 | $43.58B  | 12.52% |
| 2024-03-31 | $40.36B  | 11.80% |
| 2023-12-31 | $37.58B  | -3.26% |
| 2023-09-30 | $41.25B  | 11.50% |
| 2023-06-30 | $38.69B | -15.44% |

The ROE figures show some fluctuations, indicating a dynamic capital management strategy. Analyzing the reasons for the negative ROE in 2023 Q4 and Q2 would be critical.  

### 6. News and Recent Issues:

**Further research is needed to identify news and recent issues impacting MRK.** 

* **Specific news sources:** Look at recent articles from financial news outlets like **Bloomberg, Reuters, The Wall Street Journal, Seeking Alpha, and MarketBeat**.
* **Company website:** Check the "Investor Relations" section of Merck's website for recent press releases and SEC filings.
* **Earnings call transcripts:** Review the transcripts of the company's recent earnings calls for insights into management's outlook and strategic priorities. 
* **Analyst reports:** Search for reports from analysts like **Morningstar, Zacks, and TipRanks** for their opinions on MRK's future prospects. 
* **Financial platforms:** Use platforms like **Finbold** for additional data and analysis on MRK, including analyst opinions and performance highlights.

### 7. Comprehensive Analysis:

Merck & Co Inc (MRK) is currently trading below its moving averages, suggesting a possible downward trend.  While the RSI indicates oversold conditions and the recent earnings report shows strong revenue growth, the stock has underperformed the S&P 500 over the long term and the PPO signals weakness in price momentum. 

* **Positive factors:** Strong financial health, consistent revenue growth, and recent earnings exceeding expectations.
* **Negative factors:** Underperformance relative to the S&P 500, declining relative divergence, and some fluctuations in ROE.

**Further research on recent news, analyst opinions, and a deeper dive into the financial data is crucial to determine if MRK offers a worthwhile investment opportunity.**

### 8. Report in English: 

This report analyzes the current state of Merck & Co Inc (MRK) stock. While MRK has demonstrated strong financial performance with consistent revenue growth and a healthy profit margin, it currently lags behind the S&P 500, suggesting a need for further investigation. 

**Key takeaways:**

* MRK has underperformed the S&P 500 with a cumulative return of 61.17% against the S&P 500's 136.74%.
* The stock is trading below its moving averages, signaling potential weakness.
* The RSI suggests oversold conditions, while the PPO points to declining price momentum.
* Recent earnings were above analyst expectations, demonstrating continued revenue growth.
* However, some fluctuations in ROE require further investigation.

**To make an informed investment decision, further research is necessary. This includes:**

* Examining recent news and analyst opinions
* Analyzing the company's recent earnings call transcripts
* Comparing actual earnings with analysts' estimates
* Investigating the reasons behind fluctuations in ROE

Only after a comprehensive evaluation of these factors can investors determine whether MRK offers a compelling investment opportunity. 
